Merck to showcase advances in the science of cancer with new data presented at ASCO 2024
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Sanofi will leverage this partnership to provide access to proprietary data to develop AI models
The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States
The collaboration aims to bolster healthcare entrepreneurship
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated